Dr. Reddy's Laboratories is looking to further the company’s goal of reaching over 1.5 billion patients by 2030 after entering into the trade generics business in India with the launch of a new dedicated division, ‘RGenX’.
Moving forward, the Indian firm's branded medicines will be sold through the trade generics route, including a product brand name...